Cancer is considered to be one of the most feared diseases globally. It is a leading cause of death and disability for millions of people across the globe. Prostate cancer in men and breast cancer in women remain the most common types of cancer that are affecting Americans yearly. Moreover, there has been an increase in the cases of skin cancer and colon cancer. This way, researchers have been evaluating new ways of diagnosing and treating cancer. When cancer is detected at its early stages, it is easy for doctors to contain it.
According to the National Cancer Institute, almost 40 percent of people in the United States will be diagnosed with some type of cancer in their lifetime. Each year, over 600,000 people in the United States lose their battles with cancer. Given the shocking statistics, it is easy to feel that not much is being done to address the cancer issue along with other chronic diseases.
Presently, biotech firms such as Seattle Genetics are devising innovative of treating cancer. With professionals like Dr. Clay Siegall at the leadership of the entity, it is easy to notice why the companies are making such outstanding progress. A look at Siegall’s background shows how he has worked his way to rank as one of the revered scientists on matters of cancer research.
About Clay Siegall
Clay Siegall is the founder and CEO of a Seattle-based biotech company, Seattle Genetics. The company focuses on the development of targeted therapy drugs. Since founding Seattle Genetics, he has led the firm to rank as one of the authorities in the targeted therapy industry. The corporation has grown from a small start-up to a revered entity in conducting cancer research.
Siegall has a B.S. in zoology and a PhD in genetics. He received his education at The University of Maryland and George Washington University. Clay Siegall sits on the board of Alder Bio Pharmaceuticals. Owing to his extensive experience in research, Clay has authored more than 70 articles. Notably, the scientist holds more than 15 patents. He is a strong supporter of therapies that seek to prolong the life of cancer patients.